Viridian (VRDN) Q2 Net Loss Widens 55%
Viridian Therapeutics (NASDAQ:VRDN), a biotechnology company focused on therapies for autoimmune diseases including thyroid eye disease (TED), released its second quarter 2025 results on August 6, 2025. The report highlighted major clinical progress with its lead TED candidate, veligrotug, after positive pivotal trial results and an FDA Breakthrough Therapy Designation. Collaboration revenue (GAAP) came in at $75 thousand, ahead of the $50 thousand GAAP estimate, but still negligible due to the company’s pre-commercial phase. Net loss per share (GAAP) was $(1.00), missing analyst expectations. The quarter further clarified Viridian’s transition from clinical to commercialization activities, while its financials showed an ongoing pattern of heavy investment and widening net losses as research and development spending scaled up.
Source: Analyst estimates for the quarter provided by FactSet.
Viridian focuses on discovering and developing therapies for patients with rare and serious autoimmune diseases. Its main target is thyroid eye disease, a rare autoimmune disorder that causes inflammation and tissue changes around the eyes. The company’s scientific work centers on developing drugs that can improve safety, convenience, and efficacy compared with current therapies.
Source Fool.com
